CGT Research Outlook and Technology Growth Opportunities

CGT Research Outlook and Technology Growth Opportunities

CGT Landscape Assessment

The CGT landscape has evolved extensively over the past decade. More than 80 CGT products have been commercialized globally, with 34 FDA-approved cell and gene therapies in 2023 alone. The rise in product pipelines and clinical success rates has led to the growing demand for the development of new technology platforms, manufacturing capabilities, and expansion to new disease areas.

Over the past five years, the patent landscape, investment landscape, and clinical trial segment have had consistent growth and activity. All three segments contribute extensively to the growth of CGTs and showcase the promising potential of CGTs for the future. The CGT landscape has three main categories of therapies: cell therapies, gene therapies, and gene-modified cell therapies, with all three progressing well over the past years. Gene-modified cell therapies, such as CAR-T and CAR-NK, have a higher number of clinical programs in the pipeline and are expected to have a high clinical impact in the coming years.

CGT developers are exploring new disease areas, apart from hematological conditions and oncology, to include diabetes, cardiovascular diseases, and neurological conditions, which will boost the demand for CGTs.

The report covers the developments and trends in the CGT landscape. A collaborative environment showing the high adoption of new technologies to improve CGTs will transform the end-to-end capabilities in CGT development and manufacturing.

Patent activity is high because of consistent developments in technology for vector design, cell line manufacturing, digitalization of CGT manufacturing capabilities, and AI integration across the end-to-end CGT development. Venture capital firms see huge potential in the CGT segment in the coming years and have been constant supporters in backing start-ups and mid-sized CGT developers to accelerate their pipelines. In the coming years, the number of CGTs receiving regulatory approvals is predicted to multiply by three fold, and policies will be put in place to increase patient accessibility.